Lead Product(s) : Diclofenac
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Details : Novartis India Limited enters into an exclusive sales and distribution agreement with Dr. Reddy’s Laboratories for a few of its Established Medicines which includes the Voveran® range, the Calcium range and Methergine®.
Brand Name : Voveran
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 11, 2022
Lead Product(s) : Diclofenac
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Diclofenac
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Chromocell Corporation
Deal Size : Undisclosed
Deal Type : Partnership
Benuvia Operations and Chromocell Form Strategic Partnership for Healthcare Solutions
Details : The partnership grants Chromocell access to concentrate on the clinical advancement of a sublingual formulation of a Diclofenac spray designed for treating acute pain.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 27, 2024
Lead Product(s) : Diclofenac
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Chromocell Corporation
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Diclofenac
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DARE-PDM1 (diclofenac) is a vaginal hydrogel which inhibits Cox-1 and Cox-2. It is being evaluated in phase 1 clinical trials for the treatment of primary dysmenorrhea.
Brand Name : DARE-PDM1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 20, 2023
Lead Product(s) : Diclofenac
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Diclofenac
Therapeutic Area : Rheumatology
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Diclofenac hydrogel patches are a nonsteroidal anti-inflammatory drug (NSAIDs) products that are used to treat short-term pain due to minor strains, sprains and bruises.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 25, 2022
Lead Product(s) : Diclofenac
Therapeutic Area : Rheumatology
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Diclofenac
Therapeutic Area : Musculoskeletal
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : $40.0 million
Deal Type : Public Offering
Virpax ® Pharmaceuticals Announces Closing of a $ 40 Million Public Offering of Common Stock
Details : Virpax intends to use the net proceeds from the offering to fund research and development of the Epoladerm, Probudur, Envelta and AnQlar indications and other development programs in clinical trial.
Brand Name : Epoladerm
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 16, 2021
Lead Product(s) : Diclofenac
Therapeutic Area : Musculoskeletal
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : $40.0 million
Deal Type : Public Offering
LOOKING FOR A SUPPLIER?
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
